Biotechnology company Entos Pharmaceuticals Inc reported on Wednesday the signing of a research, development and collaboration agreement with a biopharmaceutical partner to develop novel therapeutic compounds targeting autoimmune and inflammatory diseases.
The companies will collaborate on the formulation and screening of candidates using Entos' Fusogenix non-viral delivery platform for nucleic acid therapies. Fusogenix uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi and CRISPR.
This R&D agreement provides the partner company with the option to exclusively license the candidates developed from Entos for further development and commercialisation.
As part of the agreement, Entos receives research funding and is eligible for option exercise fees and research, development, regulatory and sales milestone payments of up to USD109m from the partner.
In addition, the partner will pay Entos undisclosed royalties on sales of products resulting from the collaboration.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca